IL150463A0 - Compounds and methods for modulation of estrogen receptors - Google Patents
Compounds and methods for modulation of estrogen receptorsInfo
- Publication number
- IL150463A0 IL150463A0 IL15046300A IL15046300A IL150463A0 IL 150463 A0 IL150463 A0 IL 150463A0 IL 15046300 A IL15046300 A IL 15046300A IL 15046300 A IL15046300 A IL 15046300A IL 150463 A0 IL150463 A0 IL 150463A0
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- methods
- disclosed
- beta
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47577699A | 1999-12-30 | 1999-12-30 | |
US09/492,939 US6291456B1 (en) | 1998-12-30 | 2000-01-27 | Compounds and methods for modulation of estrogen receptors |
US09/611,156 US6331562B1 (en) | 1998-12-30 | 2000-07-06 | Compounds and methods for modulation of estrogen receptors |
PCT/US2000/035671 WO2001049673A2 (en) | 1999-12-30 | 2000-12-29 | Compounds and methods for modulation of estrogen receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
IL150463A0 true IL150463A0 (en) | 2002-12-01 |
Family
ID=27413348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15046300A IL150463A0 (en) | 1999-12-30 | 2000-12-29 | Compounds and methods for modulation of estrogen receptors |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1246814B1 (xx) |
JP (1) | JP2003519219A (xx) |
KR (1) | KR20020075388A (xx) |
CN (1) | CN1281598C (xx) |
AT (1) | ATE289300T1 (xx) |
AU (1) | AU781282B2 (xx) |
CA (1) | CA2396059A1 (xx) |
DE (1) | DE60018215T2 (xx) |
DK (1) | DK1246814T3 (xx) |
ES (1) | ES2238034T3 (xx) |
HK (1) | HK1058521A1 (xx) |
IL (1) | IL150463A0 (xx) |
PT (1) | PT1246814E (xx) |
WO (1) | WO2001049673A2 (xx) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO5271709A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
EP1177787A3 (en) * | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
EP1281710A1 (en) * | 2001-08-03 | 2003-02-05 | CHIESI FARMACEUTICI S.p.A. | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
US7148252B2 (en) * | 2001-10-03 | 2006-12-12 | Signal Pharmaceuticals, Llc | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis |
CA2467013C (en) | 2001-11-19 | 2010-08-10 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
KR100658110B1 (ko) * | 2001-11-29 | 2006-12-14 | 지티엑스, 인코포레이티드 | 안드로겐 결핍 유도 골다공증의 예방 및 치료 |
US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
AU2005202072B2 (en) * | 2001-11-29 | 2008-10-23 | Gtx, Inc. | Prevention and treatment of androgen-deprivation induced conditions |
CA2482986A1 (en) * | 2002-04-19 | 2003-10-30 | Signal Pharmaceuticals, Inc. | Benzopyranone compounds, compositions thereof, and methods of treatment therewith |
US7091235B2 (en) | 2002-10-15 | 2006-08-15 | Signal Pharmaceuticals, Llc | Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer |
US7674783B2 (en) * | 2002-11-22 | 2010-03-09 | Dimera Inc. | Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease |
EP1618102B1 (en) | 2003-04-21 | 2010-02-10 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
DK1626974T3 (da) | 2003-04-21 | 2008-11-17 | Lilly Co Eli | Substituerede benzopyraner som selektive östrogenreceptor-beta-agonister |
US7098340B2 (en) * | 2003-05-14 | 2006-08-29 | Warner Lambert Company Llc | Benzyl sulfonamide derivatives |
WO2005028472A1 (en) * | 2003-09-15 | 2005-03-31 | Signal Pharmaceuticals, Llc | Benzopyranone compounds, compositions thereof, and methods of treatment therewith |
WO2006078833A2 (en) * | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel coumarin derivatives as ion channel openers |
EP2037905B1 (en) * | 2006-06-23 | 2013-05-01 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
EP3106159A1 (en) | 2010-05-12 | 2016-12-21 | Radius Health, Inc. | Therapeutic regimens |
ES2550319T3 (es) | 2010-09-28 | 2015-11-06 | Radius Health, Inc | Moduladores selectivos del receptor de andrógenos |
EP4035664A3 (en) | 2014-03-28 | 2022-11-30 | Duke University | Treating cancer using selective estrogen receptor modulators |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
CN105801544A (zh) * | 2016-04-18 | 2016-07-27 | 中国药科大学 | 3-芳基-4-芳香胺-香豆素衍生物及其制备方法和医药用途 |
CN105801543B (zh) * | 2016-04-18 | 2019-08-02 | 中国药科大学 | 4-芳香胺-香豆素衍生物及其制备方法和医药用途 |
AU2017281038B2 (en) | 2016-06-22 | 2021-09-09 | Ellipses Pharma Ltd | AR+ breast cancer treatment methods |
CN106492204A (zh) * | 2016-12-27 | 2017-03-15 | 郑州郑先医药科技有限公司 | 一种治疗白内障的药物组合物 |
CN106727637A (zh) * | 2016-12-27 | 2017-05-31 | 郑州郑先医药科技有限公司 | 一种治疗白内障的西药组合物及其用途 |
AU2018205285C9 (en) | 2017-01-05 | 2024-05-23 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD1901-2HCl |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990077156A (ko) * | 1996-01-11 | 1999-10-25 | 한센 핀 베네드, 안네 제헤르 | 폐경기 증상의 치료 또는 예방을 위한 약학적 조성물의제조를 위한 3,4-디페닐크로만의 사용 |
US5883118A (en) * | 1996-01-11 | 1999-03-16 | Nova Nordisk A/S | Prostatic carcinoma |
US5726202A (en) * | 1996-01-11 | 1998-03-10 | Novo Nordisk A/S | Benign prostatic hypertrophy |
WO2000039120A2 (en) * | 1998-12-30 | 2000-07-06 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
-
2000
- 2000-12-29 EP EP00990966A patent/EP1246814B1/en not_active Expired - Lifetime
- 2000-12-29 JP JP2001550213A patent/JP2003519219A/ja active Pending
- 2000-12-29 WO PCT/US2000/035671 patent/WO2001049673A2/en active IP Right Grant
- 2000-12-29 IL IL15046300A patent/IL150463A0/xx unknown
- 2000-12-29 PT PT00990966T patent/PT1246814E/pt unknown
- 2000-12-29 AU AU30771/01A patent/AU781282B2/en not_active Ceased
- 2000-12-29 ES ES00990966T patent/ES2238034T3/es not_active Expired - Lifetime
- 2000-12-29 CN CNB008192227A patent/CN1281598C/zh not_active Expired - Fee Related
- 2000-12-29 AT AT00990966T patent/ATE289300T1/de not_active IP Right Cessation
- 2000-12-29 KR KR1020027008569A patent/KR20020075388A/ko active IP Right Grant
- 2000-12-29 DK DK00990966T patent/DK1246814T3/da active
- 2000-12-29 CA CA002396059A patent/CA2396059A1/en not_active Abandoned
- 2000-12-29 DE DE60018215T patent/DE60018215T2/de not_active Expired - Fee Related
-
2004
- 2004-02-20 HK HK04101233A patent/HK1058521A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE289300T1 (de) | 2005-03-15 |
AU781282B2 (en) | 2005-05-12 |
KR20020075388A (ko) | 2002-10-04 |
AU3077101A (en) | 2001-07-16 |
CN1437591A (zh) | 2003-08-20 |
HK1058521A1 (en) | 2004-05-21 |
EP1246814A2 (en) | 2002-10-09 |
CA2396059A1 (en) | 2001-07-12 |
WO2001049673A3 (en) | 2001-12-06 |
JP2003519219A (ja) | 2003-06-17 |
WO2001049673A2 (en) | 2001-07-12 |
DE60018215T2 (de) | 2006-02-09 |
EP1246814B1 (en) | 2005-02-16 |
DK1246814T3 (da) | 2005-05-30 |
DE60018215D1 (de) | 2005-03-24 |
CN1281598C (zh) | 2006-10-25 |
PT1246814E (pt) | 2005-07-29 |
ES2238034T3 (es) | 2005-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL150463A0 (en) | Compounds and methods for modulation of estrogen receptors | |
WO2000055137A8 (en) | Compounds and methods for modulation of estrogen receptors | |
HK1075893A1 (en) | Compounds and methods for modulation of estrogen receptors | |
MY115784A (en) | Estrogen agonists/antagonists | |
DE69935335D1 (de) | Pyrazole als modulatoren des östrogenrezeptors | |
AU5467699A (en) | Substituted isoxazole as estrogen receptor modulators | |
MX9505249A (es) | Agonistas de estrogeno. | |
PL372594A1 (en) | Swollen starch-latex compositions for use in papermaking | |
CR6478A (es) | Moduladores del receptor glucocorticoide | |
WO2007016385A3 (en) | Use of substituted 5-amino-1h-pyrrole-2-carbonitrile derivatives as progesterone receptor modulators | |
EA200300474A1 (ru) | Модуляторы рецепторов эстрогена | |
BR0312024A (pt) | Uso de derivados de ciclotiocarbamato no tratamento de condições relacionadas com hormÈnios | |
EP1009755A4 (en) | STEROID SULFATASE INHIBITORS AND METHODS OF PRODUCING AND USING THE SAME | |
NZ500992A (en) | Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia | |
ATE254122T1 (de) | Indolderivate als 5-ht1b und 5-ht1d agonisten | |
HK1044542B (zh) | 由11β-芳基-17,17-螺硫羥烷取代的類固醇 | |
Meyers | The role of hormone receptors in estrogen activity is questionable | |
DK0898708T3 (da) | Interaktion af cyclin D1 og estrogenreceptor og anvendelse deraf i assays | |
Charnock-Jones et al. | Vascular endothelial growth factor and corpus luteum angiogenesis | |
MY137604A (en) | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | |
Boyde | Stereographic visual aids | |
WO2003041654A3 (en) | Anti-estrogen and immune modulator combinations for treating breast cancer | |
Novaro et al. | A Cell Culture Model for Understanding Estrogen Receptor Regulation in Normal and Malignant Cells. Addendum | |
Ishii et al. | A NEW THERAPEUTIC STRATEGY FOR TARGETING TUMOR STROMA IN HORMONE-REFRACTORY PROSTATE CANCER CELL GROWTH UNDER ANDROGEN ABLATION THERAPY |